ANURAS2023-10-012023-12-31 ANURAS2023-10-012023-12-31 ANURAS2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member ANURAS2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member ANURAS2023-12-31 ANURAS2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ANURAS2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ANURAS2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ANURAS2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ANURAS2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ANURAS2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member ANURAS2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member ANURAS2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543275 ANURAS NOTLISTED Anupam Rasayan India Limited Equity 2023-04-01 2024-03-31 2024-02-12 2024-02-06 INR Millions Third quarter 09:03:00 10:10:00 2024-02-12 2024-02-12 Not applicable Single segment The Company operates only in the one revenue segment. i.e. Manufacturing of industrial chemicals. 2023-10-01 2023-12-31 Unaudited Consolidated 2955177000.00 23775000.00 2978952000.00 1472948000.00 0.00 -463528000.00 210308000.00 251313000.00 204286000.00 944648000.00 2619975000.00 358977000.00 0.00 358977000.00 -65907000.00 164675000.00 98768000.00 0.00 260209000.00 0.00 0.00 0.00 0.00 260209000.00 4688000.00 264897000.00 184083000.00 76126000.00 188606000.00 76290000.00 1095152000.00 10 1.70 1.70 0.00 0.00 1.70 1.70 [1] The above Consolidated financial results for the quarter and nine months ended December 31, 2023 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on February 12, 2024. [2] Based on the management approach as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker (CODM) evaluates the company's performance and allocates resources based on an analysis of various performance indicators of business segment/s in which the company operates. The Company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals which the management and CODM recognise as the sole business segment. Hence, disclosure of segment-wise information is not required and accordingly not provided. [3] Out of total proceeds of INR 4,999.90 Million from Qualified Institutions Placement (QIP) INR 3,057.90 million has been utilised for Capex projects, general corporate purpose and INR 313.00 Million for Issue related expenses upto December 31, 2023 as per object of QIPs Placement Documents filed with Securities and Exchange Board of India (SEBI) on October 03, 2022 and balance proceeds of INR 1,629.00 Million are lying with Bank Accounts and Fixed Deposits with Banks. [4] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary. [5] Subsequent to the quarter-end, the Company has allotted 39,14,886 warrants convertible into equal number of equity shares within 18 months from the date of allotment, to the specified allottees at Rs. 945.11/- per warrant by way of preferential issue. [6] Out of total proceeds received for allotment of equity shares by way of preferential issue during the quarter, INR 1,800.00 Million, INR 56.25 million has been utilised for repayment of Loan as per object of the issue and balance proceeds of INR 1,743.75 Million are lying with Bank Accounts and Fixed Deposits with Banks. Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 10740566000.00 182114000.00 10922680000.00 5642948000.00 0.00 -1377972000.00 581472000.00 633617000.00 589570000.00 3014408000.00 9084043000.00 1838637000.00 0.00 1838637000.00 231134000.00 337847000.00 568981000.00 0.00 1269656000.00 0.00 0.00 0.00 0.00 1269656000.00 3038000.00 1272694000.00 976986000.00 292670000.00 979343000.00 293351000.00 1095152000.00 10 9.08 9.05 0.00 0.00 9.08 9.05 Other Expenses 944648000.00 Other Expenses 3014408000.00 Gain/(loss) on remeasurements of the defined benefits plan 2672000.00 Income tax (expense)/income on remeasurements of the defined benefits plan -761000.00 Gain/(loss) on remeasurements of the defined benefits plan 4608000.00 Income tax (expense)/income on remeasurements of the defined benefits plan -1288000.00 1911000.00 3320000.00 0.00 0.00 Effective portion of gain/(loss) on hedging instruments in a cash flow hedge 3917000.00 Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge -1140000.00 Effective portion of gain/(loss) on hedging instruments in a cash flow hedge -397000.00 Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge 115000.00 2777000.00 -282000.00 0.00 0.00